Abeona Therapeutics (ABEO)

Its lead commercial product is ZEVASKYN, also known as prademagene zamikeracel, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa. RDEB is a rare inherited skin disorder caused by mutations affecting type VII collagen, leaving patients prone to severe blistering, chronic wounds, scarring, pain, and infection risk. ZEVASKYN uses a patient’s own cells that are genetically modified and then returned as engineered skin sheets intended to treat wounds associated with the disease.

Beyond its commercial-stage work in RDEB, Abeona maintains a development portfolio that includes AAV-based gene therapy candidates for ophthalmic diseases with significant unmet medical need. AAV vectors are widely used in genetic medicine because they can deliver therapeutic genetic material to targeted tissues, including the eye, where localized administration may be possible.

As a listed biotechnology company, Abeona’s business is shaped by manufacturing execution, regulatory requirements, patient access, and adoption by specialist treatment centers. Its position is distinctive because it combines rare disease gene therapy expertise with a product aimed at one of the most severe dermatologic genetic disorders, while continuing to pursue pipeline opportunities in inherited eye disease.